



IFW

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Docket No: **A8340**

Gillian PAYNE et al

Conf. No.: **4835**

Appln. No.: **10/612,090**

Group Art Unit: **1643**

Filed: **July 3, 2003**

Examiner: **Tungaturthi, P.**

For: **ANTIBODIES TO NON-SHED MUC1 AND MUC16, AND USES THEREOF**

STATEMENT UNDER 37 C.F.R. § 1.97(e)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The undersigned hereby states, upon information and belief:

That each item of information contained in the Supplemental Information Disclosure Statement filed concurrently herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of said Supplemental Information Disclosure Statement.

Respectfully submitted,



Drew Hissong
Registration No. 44,765

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: March 9, 2006



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Gillian PAYNE et al

Appln. No.: 10/612,090

Filed: July 3, 2003

Docket No: A8340

Conf. No.: 4835

Group Art Unit: 1643

Examiner: Tungaturthi, P.

For: ANTIBODIES TO NON-SHED MUC1 AND MUC16, AND USES THEREOF

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98**

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicants hereby notify the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form which the Examiner may deem material to patentability of the claims of the above-identified application.

A copy of each of the listed documents (along with a copy of the corresponding Communication from a Foreign Patent Office) is submitted herewith.


The present Supplemental Information Disclosure Statement is being filed after three months from the application's filing date and after the mailing date of the first Office Action on the merits. Therefore, Applicants are filing concurrently herewith a Statement Under 37 C.F.R. § 1.97(e). No fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicants do not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
U.S. Appln. No. 10/612,090**

The U.S. Patent and Trademark Office is hereby directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,



Drew Hissong
Registration No. 44,765

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: March 9, 2006

Substitute for Form 1449 A & B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) MAR 09 2006

Sheet

1

10

Application No. 1 10/612,000

Application Number	10/612,090
Confirmation Number	4835
Filing Date	July 3, 2003
First Named Inventor	Gillian PAYNE et al
Art Unit	1643
Examiner Name	Tungaturthi, P.
Attorney Docket Number	A8340

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

NON PATENT LITERATURE DOCUMENTS

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		O'Brien et al, <i>Tumor Biology</i> , 22(6):348-366 (2001)	
		Pietersz et al, <i>Vaccine</i> , 18(19):2059-2071 (2000)	
		Taylor-Papadimitriou et al, <i>Biochimica et Biophysica ACTA, Molecular Basis of Disease</i> , 1455(2-3):301-313 (1999)	

Examiner Signature _____ **Date Considered** _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.